Case Study: Novel Approach to HIV-Associated Neuropathy Platelet Rich Plasma Successful in Treating HIV-Associated Peripheral Neuropathy
DOI:
https://doi.org/10.12970/2309-0529.2013.01.02.2Keywords:
Distal symmetrical peripheral neuropathy, H.I.V. neuropathy, neurogenic growth factors, platelet-rich-plasma, nerve pain.Abstract
Distal symmetrical peripheral neuropathy (DSPN) is the most common neurologic complication of Human Immunodeficiency Virus (HIV) infection. DSPN is a distressing pain syndrome and infected patients have limited treatment options for alleviating symptoms. Platelet Rich Plasma has been found to be effective in relieving pain associated with chronic and acute musculoskeletal conditions as well as arthritic conditions. We tested the hypothesis that platelet rich plasma alleviates symptoms of HIV-associated DSPN. A 50year-old African American patient was referred for long-standing bilateral leg neuropathy. The patient was treated with an injection of platelet rich plasma therapy ever two weeks for 12 weeks. The treatment outcomes were pain intensity, pain relief, sensory perception, quality of life, mood, and function. After the first therapeutic injection of platelet rich plasma, the patient reported significant improvement in pain relief, sensory perception, and range of motion. The therapy was effective in relieving pain so the patient discontinued use all other pain medications including Vicodin and Neurontin. This case report provides evidence that platelet rich plasma is effective in relieving painful numbness, tingling and burning related to HIV-associated DSPN. Platelet rich plasma may be a valuable option for treatment of symptoms associated with DSPN among HIV patients.References
[1] Ferrari S, Vento S, Monaco S, et al. Human immunodeficiency virus-associated peripheral neuropathies. Mayo Clin Proc 2006; 81(2): 213-9. http://dx.doi.org/10.4065/81.2.213
[2] Evans SR, Ellis RJ, Chen H, et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011; 25(7): 919-28. http://dx.doi.org/10.1097/QAD.0b013e328345889d
[3] Schifitto G, Yiannoutsos CT, Simpson DM, et al. A placebocontrolled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J Neurovirol 2006; 12(4): 328-31. http://dx.doi.org/10.1080/13550280600873835
[4] Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS ONE 2010; 5(12): e14433. http://dx.doi.org/10.1371/journal.pone.0014433
[5] Simpson DM, Dorfman D, Olney RK, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology 1996; 47(5): 1254-9. http://dx.doi.org/10.1212/WNL.47.5.1254
[6] Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis ofrandomised controlled trials. PLoS ONE 2010; 5(12): e14433. http://dx.doi.org/10.1371/journal.pone.0014433
[7] Treede, R-D, et al. Mechanism-and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain. Curr Med Res Opinion 2013; 29(5): 527-538. http://dx.doi.org/10.1185/03007995.2013.781019
[8] Kuffler Damien P. Platelet-Rich Plasma and the Elimination of Neuropathic Pain. Mol Neurobiol 2013; 1-18.
[9] Lacci Kathleen M, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med 2010; 83(1): 1.
[10] Griffin XL, Smith CM, Costa ML. The clinical use of plateletrich plasma in the promotion of bone healing: a systematic review. Injury 2009; 40(2): 158-162. http://dx.doi.org/10.1016/j.injury.2008.06.025
[11] Mehta S, Watson JT. Platelet rich concentrate: basic science and current clinical applications. J Orthop Trauma 2008; 22(6): 432-438. http://dx.doi.org/10.1097/BOT.0b013e31817e793f
[12] Everts PA, Brown Mahoney C, Hoffmann JJ, et al. Plateletrich plasma preparation using three devices: implications for platelet activation and platelet growth factor release. Growth Factors 2006; 24(3): 165-171. http://dx.doi.org/10.1080/08977190600821327
[13] Sampson S, et al. Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabilit 2010; 89(12): 961-969. http://dx.doi.org/10.1097/PHM.0b013e3181fc7edf
[14] Oxford Textbook of Palliative Medicine, Oxford University Press 1993; 109.
[15] McAleer JP, Sharma S, Kaplan EM, Persich G. Use of autologous platelet concentrate in a nonhealing lower extremity wound. Adv Skin Wound Care 2006; 19(7): 354- 363. http://dx.doi.org/10.1097/00129334-200609000-00010
[16] Salemi S, Rinaldi C, Manna F, Guarneri GF, Parodi PC. Reconstruction of lower leg skin ulcer with autologous adipose tissue and platelet-rich plasma. J Plast Reconstr Aesthet Surg 2008; 61(12): 1565-1567. http://dx.doi.org/10.1016/j.bjps.2008.04.048
[17] Margolis DJ, Kantor K, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001; 24(3): 483-488. http://dx.doi.org/10.2337/diacare.24.3.483
[18] Crovetti G, Martinelli G, Issi M, et al. Platelet gel for healing cutaneous chronic wounds.Transfus Apher Sci 2004; 30(2): 145-151. http://dx.doi.org/10.1016/j.transci.2004.01.004
[19] O’Connell SM, Impeduglia T, Hessler K, Wang XJ, Carroll RJ, Dardik H. Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. Wound Repair Regen 2008; 16(6): 749-756. http://dx.doi.org/10.1111/j.1524-475X.2008.00426.x
[20] Bhanot S, Alex JC. Current applications of platelet gels in facial plastic surgery. Facial Plast Surg 2002; 18(1): 27-33. http://dx.doi.org/10.1055/s-2002-19824
[21] Driver VR, Hanft J, Fylling CP, Beriou JM. Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 2006; 52(6): 68-70, 72, 74 passim.
[22] Schifitto G, Yiannoutsos C, Simpson DM, et al. Long-term treatment with recombinant nerve growth factor for HIVassociated sensory neuropathy. Neurology 2001; 57(7): 1313-6. http://dx.doi.org/10.1212/WNL.57.7.1313
[23] Mcarthur JC, Yiannoutsos C, Simpson DM, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 2000; 54(5): 1080-8. http://dx.doi.org/10.1212/WNL.54.5.1080